Spastic Paraplegia Type 4 Latest Advances

Clinical and genetic characterization of hereditary spastic paraplegia type 4 in a Taiwanese cohort.

Journal: Parkinsonism & related disorders

Published: May 25, 2026

SPG4 Hereditary Spastic Paraplegia: From Etiology to Therapy.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: April 28, 2026

Validation of a Cellular Imaging-Based Method as a Potential Biomarker for SPG4 Hereditary Spastic Paraplegia.

Journal: Annals of clinical and translational neurology

Published: March 27, 2026

Significant differences in phenotype and age of onset in an SPG4 family caused by whole SPAST deletion combined with a hemizygous S44L modifier.

Journal: Neurogenetics

Published: March 16, 2026

Reorganization of functional brain network architecture in SPG4: Evidence from resting-state fMRI.

Journal: Parkinsonism & related disorders

Published: March 09, 2026

Expanding the clinical and mutational spectrum of hereditary spastic paraplegia type 4 in a cohort of patients from central China.

Journal: Frontiers in genetics

Published: January 31, 2026

Fampridine in Hereditary Spastic Paraplegia Type 4 With SPAST Variant c.683-2A>C: A Case Report.

Journal: The American journal of case reports

Published: January 07, 2026

An MRI-based radiomics model for precision subtyping of hereditary spastic paraplegia: discriminating SPG4 from SPG5.

Journal: Neuroradiology

Published: November 23, 2025

A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase VCPIP1 to Lower SPASTIN Levels.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: November 20, 2025

SPG4 and Dementia: Expanding the Clinical Spectrum.

Journal: Annals of clinical and translational neurology

Published: November 14, 2025

Genotype-structure-phenotype correlations define divergent natural history in early-onset spastic paraplegia type 4.

Journal: Brain : a journal of neurology

Published: October 09, 2025

Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: September 17, 2025

Spastic Paraplegia Type 4 Latest Advances

Find the Latest Research About Spastic Paraplegia Type 4

Clinical and genetic characterization of hereditary spastic paraplegia type 4 in a Taiwanese cohort.

Clinical and genetic characterization of hereditary spastic paraplegia type 4 in a Taiwanese cohort.

SPG4 Hereditary Spastic Paraplegia: From Etiology to Therapy.

SPG4 Hereditary Spastic Paraplegia: From Etiology to Therapy.

Validation of a Cellular Imaging-Based Method as a Potential Biomarker for SPG4 Hereditary Spastic Paraplegia.

Validation of a Cellular Imaging-Based Method as a Potential Biomarker for SPG4 Hereditary Spastic Paraplegia.

Significant differences in phenotype and age of onset in an SPG4 family caused by whole SPAST deletion combined with a hemizygous S44L modifier.

Significant differences in phenotype and age of onset in an SPG4 family caused by whole SPAST deletion combined with a hemizygous S44L modifier.

Reorganization of functional brain network architecture in SPG4: Evidence from resting-state fMRI.

Reorganization of functional brain network architecture in SPG4: Evidence from resting-state fMRI.

Expanding the clinical and mutational spectrum of hereditary spastic paraplegia type 4 in a cohort of patients from central China.

Expanding the clinical and mutational spectrum of hereditary spastic paraplegia type 4 in a cohort of patients from central China.

Fampridine in Hereditary Spastic Paraplegia Type 4 With SPAST Variant c.683-2A>C: A Case Report.

Fampridine in Hereditary Spastic Paraplegia Type 4 With SPAST Variant c.683-2A>C: A Case Report.

An MRI-based radiomics model for precision subtyping of hereditary spastic paraplegia: discriminating SPG4 from SPG5.

An MRI-based radiomics model for precision subtyping of hereditary spastic paraplegia: discriminating SPG4 from SPG5.

A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase VCPIP1 to Lower SPASTIN Levels.

A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase VCPIP1 to Lower SPASTIN Levels.

SPG4 and Dementia: Expanding the Clinical Spectrum.

SPG4 and Dementia: Expanding the Clinical Spectrum.

Genotype-structure-phenotype correlations define divergent natural history in early-onset spastic paraplegia type 4.

Genotype-structure-phenotype correlations define divergent natural history in early-onset spastic paraplegia type 4.

Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4.

Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4.